DAWN (Day One Biopharmaceuticals) Debt-to-Asset : 0.01 (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

DAWN Day One Biopharmaceuticals Inc DAWN
12 GF Score
Price $21.53
! 5 Warning Signs
View Full Analysis

What is Day One Biopharmaceuticals Debt-to-Asset?

Day One Biopharmaceuticals DAWN 12 Debt-to-Asset is 0.01 as of Dec. 2025. GuruFocus rates DAWN with a GF Score™ of 12/100. The stock has 5 warning signs investors should review.

Day One Biopharmaceuticals's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2025 was $0.2 Mil. Day One Biopharmaceuticals's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2025 was $2.6 Mil. Day One Biopharmaceuticals's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Dec. 2025 was $507.8 Mil. Day One Biopharmaceuticals's debt to asset for the quarter that ended in Dec. 2025 was 0.01.

Day One Biopharmaceuticals  (NAS:DAWN) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Day One Biopharmaceuticals Debt-to-Asset Related Terms

Day One Biopharmaceuticals Debt-to-Asset Historical Data

* Premium members only.

The historical data trend for Day One Biopharmaceuticals's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Day One Biopharmaceuticals Debt-to-Asset Chart

Day One Biopharmaceuticals Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Debt-to-Asset
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.01

Day One Biopharmaceuticals Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Debt-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.01 0.01 0.01 0.01

DAWN vs TYRA, DFTX, MLYS: Debt-to-Asset Comparison

For the Biotechnology subindustry, Day One Biopharmaceuticals's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Day One Biopharmaceuticals Debt-to-Asset vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Day One Biopharmaceuticals's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Day One Biopharmaceuticals's Debt-to-Asset falls into.


DAWN
12GF Score
Day One Biopharmaceuticals Inc DAWN
Debt-to-Asset is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Day One Biopharmaceuticals Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Day One Biopharmaceuticals's Debt-to-Asset for the fiscal year that ended in Dec. 2025 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(0.174 + 2.619) / 507.827
=0.01

Day One Biopharmaceuticals's Debt-to-Asset for the quarter that ended in Dec. 2025 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(0.174 + 2.619) / 507.827
=0.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Debt-to-Asset →
What does a Debt-to-Asset of 0.01 mean?
Day One Biopharmaceuticals (DAWN) has a Debt-to-Asset of 0.01 as of Dec. 2025. Debt-to-asset ratio represents the ratio of total debt to total assets. View historical data on Day One Biopharmaceuticals and its competitors.
Is Day One Biopharmaceuticals' Debt-to-Asset too high?
Day One Biopharmaceuticals' current Debt-to-Asset is 0.01. Overall, Day One Biopharmaceuticals has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Day One Biopharmaceuticals' Debt-to-Asset compare to TYRA and DFTX?
Day One Biopharmaceuticals' Debt-to-Asset of 0.01 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Asset for a Biotechnology company?
A good Debt-to-Asset depends on the Biotechnology industry context. However, Debt-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Asset mean?
A high Debt-to-Asset can signal that a stock is expensive relative to its fundamentals. Debt-to-asset ratio represents the ratio of total debt to total assets. View historical data on Day One Biopharmaceuticals and its competitors. Day One Biopharmaceuticals's current Debt-to-Asset is 0.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Day One Biopharmaceuticals stock overvalued right now?
Day One Biopharmaceuticals (DAWN) has a current Debt-to-Asset of 0.01. The current Debt-to-Asset is 0.01. Day One Biopharmaceuticals' overall GF Score™ is 12/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Asset calculated?
Debt-to-Asset is calculated from a company's financial statements. For Day One Biopharmaceuticals (DAWN), the current Debt-to-Asset is 0.01 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Day One Biopharmaceuticals Business Description

Address 1800 Sierra Point Parkway, Suite 200, Brisbane, CA, USA, 94005
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY301 is an antibody drug conjugate (ADC) that has shown antitumor activity in preclinical models.
12GF Score

Get the complete analysis for DAWN

Debt-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$21.53
Price